Nutriband (NASDAQ: NTRB) has been granted U.S. patent No. 12,318,492 for its “Abuse and Misuse Deterrent Transdermal Systems,” further strengthening domestic protection for its Aversa(TM) technology. The patent, issued June 3, 2025, enhances the company’s intellectual property portfolio for abuse-deterrent … Continue reading →

As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming … Continue reading →

Serguei Melnik, Founder and President of Nutriband (NASDAQ: NTRB), recently joined The Smart Money Circle Show, where he pulled back the curtain on his no-nonsense approach to biotech entrepreneurship. His grounded tone and unwavering focus on long-term value stand in stark contrast … Continue reading →

Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, June 5 at 4 p.m. ET. The session will feature a fireside-style Q&A open to live audience questions, with 1×1 … Continue reading →

Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, Walmart, Walgreens, and CVS. The company continues to prioritize shareholder value by … Continue reading →

Nutriband (NASDAQ: NTRB) is featured in the latest episode of The BioMedWire Podcast, part of IBN’s expanding podcast network focused on biotech and pharmaceutical innovation. In a conversation with host Carmel Fisher, Nutriband Co-Founder and CEO Gareth Sheridan outlined the company’s … Continue reading →

In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 (https://ibn.fm/9K5zT). At the center of the company’s positive outlook for future is noteworthy progress made toward the … Continue reading →

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, … Continue reading →

As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient … Continue reading →

A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved … Continue reading →